Linked Life Data

9142773

Source:http://linkedlifedata.com/resource/pubmed/id/9142773

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1997-7-17
pubmed:abstractText
We examined the efficacy and toxicity of single daily dosing (SDD) of aminoglycosides for febrile, immunocompromised adults by systematically reviewing four randomized, controlled trials of SDD vs. standard dosing regimens. We assessed the methodological quality of each study and extracted data pertaining to efficacy and toxicity outcomes. Pooled risk ratios for the efficacy outcomes were bacteriologic cure, 1.00 (95% confidence interval [CI], 0.86-1.16); clinical cure, 0.97 (95% CI, 0.91-1.05); and mortality, 0.93 (95% CI, 0.62-1.41). The pooled nephrotoxicity risk ratio was 0.78 (95% CI, 0.31-1.94). Only one study assessed ototoxicity. Although our study was limited by the small number of trials available for review, the results suggest that SDD of aminoglycosides may be efficacious for febrile, immunocompromised patients. Additional studies are necessary for more precise quantification of the mortality and toxicity risk ratios.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1058-4838
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
810-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review.
pubmed:affiliation
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
pubmed:publicationType
Journal Article, Review